Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record.

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

Open access
for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland, Betticher, D C, Hsu Schmitz, S-F, Tötsch, M, Hansen, E, Joss, C, von Briel, C, Schmid, R A, Pless, M, Habicht, J, Roth, A D, Spiliopoulos, A, Stahel, R, Weder, W, Stupp, R, Egli, F, Furrer, M, Honegger, H, Wernli, M, Cerny, T, Ris, H-B · 2006 · British Journal of Cancer

Abstract

The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603075

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 207

Metadata

Authors
for the Swiss Group for Clinical Cancer Research (SAKK), B., Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., Spiliopoulos, A., Stahel, R., Weder, W., Stupp, R., Egli, F., Furrer, M., Honegger, H., Wernli, M., Cerny, T., & Ris, H.-B.
Venue
British Journal of Cancer
Published
2006-04
Volume
94
Issue
8
Pages
1099-1106
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1985971363
Cited by
207
References
0
FWCI
10.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. https://app.cochat.ai/papers/10.1038/sj.bjc.6603075
The paper
for the Swiss Group for Clinical Cancer Research (SAKK), B., Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., Spiliopoulos, A., Stahel, R., Weder, W., Stupp, R., Egli, F., Furrer, M., Honegger, H., Wernli, M., . . . Ris, H.-B. (2006). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603075

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.